```html

Exanthematous Drug Rash – Comprehensive Medical Guide

Overview

Exanthematous drug rash is a type of skin eruption that appears after exposure to a medication. The term “exanthem” describes a widespread, often symmetric rash that covers large body surface areas, while “drug” indicates that the reaction is triggered by a medication rather than an infection or autoimmune disease.

Most cases are morbilliform (measles‑like) and present as pink or red macules and papules that may merge into larger plaques. The rash typically begins 5–14 days after the offending drug is started, though it can appear sooner in patients who have been previously sensitized.

• Who it affects: Anyone can develop an exanthematous drug rash, but the highest incidence is seen in adults aged 20‑60 years, especially women (approximately 60% of reported cases) and people with a history of drug allergies.
• Prevalence: Drug eruptions constitute 2–5% of all emergency‑department visits for dermatologic complaints in the United States, and exanthematous rashes account for ~70% of those drug‑related skin reactions (CDC, 2023).

Symptoms

The clinical picture can vary, but the following features are commonly reported:

• Red, maculopapular rash: Small, flat or raised lesions that usually start on the trunk and spread to the neck, arms, and legs.
• Itching (pruritus): Mild to moderate itching is typical; severe itching may suggest a more extensive reaction.
• Fever: Low‑grade fever (≤38.5 °C / ≤101.3 °F) occurs in 30–40% of cases.
• Facial flushing: Warm, erythematous cheeks without vesicles.
• Symmetrical distribution: Rash often mirrors on both sides of the body.
• Onset timing: Usually 5–14 days after drug initiation; sometimes within hours if the patient is previously sensitized.
• Resolution: Rash usually fades within 7–10 days after the offending drug is discontinued, though post‑inflammatory hyperpigmentation may linger.

Less common but noteworthy symptoms that may accompany an exanthematous drug rash include:

• Swelling of the lips or face (angioedema)
• Joint pain or malaise
• Oral mucosal erythema (without ulceration)

Causes and Risk Factors

Common Culprit Medications

Over 100 drugs have been implicated. The most frequently reported classes are:

• Antibiotics – especially β‑lactams (penicillins, cephalosporins) and sulfonamides
• Non‑steroidal anti‑inflammatory drugs (NSAIDs)
• Anticonvulsants – carbamazepine, phenytoin, lamotrigine
• Allopurinol
• Antiretrovirals and antituberculosis agents

Risk Factors

• Previous drug allergy: Prior sensitization dramatically increases risk.
• Genetic predisposition: Certain HLA alleles (e.g., HLA‑B*57:01 with abacavir) are linked to higher incidence.
• Age: Elderly patients have reduced drug metabolism, prolonging exposure.
• Female sex: Hormonal and immunologic differences may play a role.
• Polypharmacy: Taking multiple medications simultaneously raises the chance of an idiosyncratic reaction.
• Renal or hepatic impairment: Impaired clearance can increase drug concentrations.

Diagnosis

Diagnosing an exanthematous drug rash is primarily clinical, relying on pattern recognition and a thorough medication history.

Step‑by‑step approach

1. History taking: Document all prescription, over‑the‑counter, herbal, and supplement use within the past month.
2. Temporal correlation: Identify a drug that started 5–14 days before rash onset.
3. Physical examination: Note distribution, morphology, and presence of systemic signs (fever, lymphadenopathy).
4. Rule out mimickers: Viral exanthems, autoimmune diseases (lupus), and other drug eruptions (e.g., urticaria, Stevens‑Johnson syndrome).

Laboratory & Diagnostic Tests

• Complete blood count (CBC): May reveal eosinophilia (common in drug reactions).
• Liver & kidney panels: Evaluate for organ involvement; elevated transaminases can accompany severe drug eruptions.
• Skin biopsy: Reserved for atypical cases; histology typically shows superficial perivascular lymphocytic infiltrate with eosinophils.
• Patch testing: Useful for identifying the specific drug in delayed‑type hypersensitivity; performed by a dermatologist after the rash resolves.

References: Mayo Clinic; CDC, 2023; National Institute of Allergy and Infectious Diseases (NIAID).

Treatment Options

The cornerstone of management is immediate discontinuation of the suspected offending drug.

Pharmacologic Measures

• Antihistamines: Second‑generation agents (cetirizine, loratadine) reduce pruritus without sedation.
• Topical corticosteroids: Low‑ to mid‑potency steroids (hydrocortisone 1% or triamcinolone 0.1%) applied twice daily can calm inflammation.
• Systemic corticosteroids: Oral prednisone 0.5 mg/kg/day for 5–7 days may be considered for extensive rash or when associated with fever.
• Cool compresses and emollients: Provide symptomatic relief and maintain skin barrier integrity.

Procedural & Supportive Care

• Hydration: Adequate oral fluids help maintain skin turgor.
• Bathing: Lukewarm baths with colloidal oatmeal can soothe itching.
• Monitoring: Daily assessment for evolution into severe cutaneous adverse reactions (SCARs) such as Stevens‑Johnson syndrome.

When to Use Systemic Therapy

Systemic steroids are reserved for:

• Rash covering >30% body surface area
• Accompanying systemic symptoms (fever >38.5 °C, malaise)
• Evidence of organ involvement (elevated liver enzymes, eosinophilia >1,500 cells/µL)

Living with Exanthematous Drug Rash

Most patients recover fully, but the experience can be uncomfortable and anxiety‑provoking. Practical tips include:

• Maintain a medication diary: Write down every drug taken, dose, and start date.
• Skin care routine: Use fragrance‑free moisturizers twice daily; avoid harsh soaps.
• Protect from sunlight: UV exposure can exacerbate erythema; apply broad‑spectrum SPF 30+.
• Clothing choices: Soft, breathable fabrics (cotton, bamboo) reduce irritation.
• Stress management: Stress can worsen itching; consider mindfulness or gentle yoga.
• Follow‑up appointments: See your dermatologist or primary‑care provider within 1–2 weeks after rash resolution to confirm healing and discuss future drug choices.

Prevention

1. Allergy documentation: Keep an up‑to‑date list of known drug allergies; share it with every prescriber.
2. Pharmacogenetic testing: For high‑risk drugs (e.g., carbamazepine in Asian populations), HLA screening can prevent severe reactions.
3. Start low, go slow: When initiating a new medication known for rash risk, clinicians may use the lowest effective dose and monitor closely.
4. Avoid self‑medication: Never start over‑the‑counter antibiotics or NSAIDs without professional guidance.
5. Review medication lists regularly: Especially after hospital discharge or when adding new therapies.

Complications

If left unchecked, an exanthematous drug rash can progress to more serious conditions:

• Secondary bacterial infection: Scratching can breach the skin barrier; look for crusting, pus, or increasing pain.
• Hypersensitivity syndromes: DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms) presents with rash, fever, lymphadenopathy, and organ involvement; mortality up to 10%.
• Stevens‑Johnson syndrome / Toxic epidermal necrolysis (TEN): Though rare, they can begin as a maculopapular rash and rapidly evolve into painful skin detachment. Prompt recognition is life‑saving.
• Post‑inflammatory hyperpigmentation or scarring: May cause cosmetic concerns, especially in darker skin types.

When to Seek Emergency Care

For non‑urgent concerns, contact your primary‑care provider or dermatologist within 24‑48 hours.

---

Sources: Mayo Clinic. “Drug rash (exanthematous).” 2023; CDC. “Adverse Drug Events in the United States.” 2023; National Institutes of Health (NIH). “Drug Hypersensitivity.” 2022; WHO. “Pharmacovigilance.” 2021; Cleveland Clinic. “Stevens‑Johnson Syndrome & Toxic Epidermal Necrolysis.” 2022.

```